Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

Riferimento: 
World J Gastroenterol. 2010 Jun 28;16(24):2963-70.
Autori: 
Strosberg J, Kvols L.
Fonte: 
World J Gastroenterol. 2010 Jun 28;16(24):2963-70.
Anno: 
2010
Azione: 
I pazienti con bassa massa totale del tessuto tumorale, nei tumori neuroendocrini metastatici dell'intestino medio, hanno più probabilità di sperimentare la stabilizzazione della malattia con octreotide LAR.
Target: 
octreotide LAR/tumori neuroendocrini metastatici dell'intestino medio.

ABSTRACT
Somatostatin analogs were initially developed for the control of hormonal syndromes associated with neuroendocrine tumors (NETs). In recent years, accumulating data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in patients with metastatic neuroendocrine malignancies, including carcinoid and pancreatic endocrine tumors. A phase III, randomized, placebo-controlled trial has now demonstrated that octreotide long-acting repeatable (LAR) 30 mg can significantly prolong time to tumor progression among patients with metastatic midgut NETs regardless of functional status, chromogranin A level or age. In addition to significantly lengthening time to tumor progression in the overall study population, subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization with octreotide LAR 30 mg, supporting the early use of octreotide LAR in patients with metastatic disease. Further research efforts are underway to evaluate the use of somatostatin analogs as antiproliferative agents in other types of gastroenteropancreatic-NETs. Ongoing studies are also evaluating novel somatostatin analogs and somatostatin analogs in combination with other anti-tumor therapies.

Free PMC Article